IDEX Biometrics issues a Convertible Bond to prepare for commercial ramp-up
Oslo, Norway – 7 November 2023 – IDEX Biometrics (Idex or the Company) has entered into a non-binding term sheet with a new institutional investor group to issue a senior convertible bond for up to 100 million NOK. The convertible bond structure is subject to approval of the formal agreements and shareholder approval.
The convertible bond will be issued at a price of 92% of the principal amount, and will be amortized over 3,5 years through instalment every 2 months over the period. The instalment periods may be altered during the amortizing period. Idex may choose repayment between equity and cash for each instalment. Interest rate is 6% pa. Conversion price will be at a premium to the stock price at closing of the final agreements and any repayments by issuance of shares will be at a discount to market price at each instalment.
To approve the convertible bond, IDEX Biometrics will call for an extraordinary meeting (EGM) on or about 30 November 2023 at 10:00 hours CET, held as an online meeting. The notice of the EGM with attendance forms will be sent to the shareholders soonest. The notice of the EGM will also be disclosed in a notice to the market.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara7.12.2023 18:00:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 7 December 2023 at 7.00 p.m. (EET) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________ Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes Oyj LEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number: 743700BYSBP0PCR6N767_20231207173757_8 ____________________________________________ Transaction date: 2023-12-04 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000260583 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 133,850 Unit price: 0.005 EUR Aggregated transactions (1): Volume: 133,850 Volume weighted average price: 0.005 EUR ____________________________________________ Transaction date: 2023-12-05 Venue not applicable Instrument
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: publication of a transparency notification7.12.2023 18:00:00 CET | Press release
Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant la communication relative à une notification de transparence. Attachments ENG_transparency notification_20231201_FINNL_transparency notification_20231201_FINFR_transparency notification_20231201_FIN
75% Load Factor, 42% increase in passenger numbers and demand picking up7.12.2023 17:50:00 CET | Press release
75% Load Factor, 42% increase in passenger numbers and demand picking up PLAY airlines carried 107,236 passengers in November, which is a 42% increase from November 2022 when PLAY carried 75,396 passengers. The load factor in November 2023 was 74.5%, down from 79% last year. This decline in load factor is a direct result of the seismic activity in the Reykjanes Peninsula and resulting global news coverage of a possible volcanic eruption that could disrupt aviation. This situation impacted last-minute bookings in the month. PLAY had an on-time performance of 88.9% in November 2023. Despite the decline in load factor in November we continued to see year-on-year growth in our unit revenue (RASK), even with a 54% growth in available seat kilometers (ASK).Average ancillary revenue continues to rise for PLAY, being 30% higher in November 2023 compared to November 2022, and the trend is looking strong for the coming months. Of all passengers flying with PLAY in November 2023, 26.2% were depar
Innofactor Plc: Share Repurchase 7.12.20237.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 7.12.2023Innofactor Plc: Share Repurchase 7.12.2023In the Helsinki Stock ExchangeTrade date 7.12.2023Bourse trade BuyShare IFA1VAmount 4,500SharesAverage price/ share 1.1494EURTotal cost 5,172.30EURInnofactor Plc now holds a total of 575 629 sharesincluding the shares repurchased on 7.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_7.12_trades
Coloplast A/S - Skift af revisor7.12.2023 17:29:40 CET | pressemeddelelse
I dag, den 7. december 2023, har Coloplast A/S afholdt ordinær generalforsamling, hvor EY Godkendt Revisionspartnerselskab blev valgt som Coloplast A/S’ revisor i overensstemmelse med forslaget fra bestyrelsen. For yderligere information, kontakt venligst Investorer og analytikere Anders Lonning-Skovgaard Koncerndirektør, CFO Tlf. 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tlf. 4911 1800 / 4911 2458 E-mail: email@example.com Kristine Husted Munk Senior Manager, Investor Relations Tlf. 4911 1800 / 4911 3266 E-mail: firstname.lastname@example.org Presse og medier Peter Mønster Sr. Media Relations Manager Tlf. 4911 2623 Email: email@example.com Adresse Coloplast A/S Holtedam 1 3050 Humlebæk Danmark CVR Nr. 69749917 Hjemmeside www.coloplast.com Denne selskabsmeddelelse foreligger på dansk og engelsk. I tvivlstilfælde er den engelske version gældende. Coloplast blev grundlagt på passion, ambition og engagement. Vi opstod på grundlag af en sygeplejerskes ønske om at hjælpe